Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

331 ARTÍCULOS , VIENDO DEL 271 AL 285

Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery

Sarvaiya J, Agrawal YK.

Int J Biol Macromol. 2015 Jan;72:454-65. doi: 10.1016/j.ijbiomac.2014.08.052. Epub 2014 Sep 6.

Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants

Di Domenico F, Barone E, Perluigi M, Butterfield DA.

Expert Rev Neurother. 2015 Jan;15(1):19-40. doi: 10.1586/14737175.2015.955853. Epub 2014 Sep 22.

[Alzheimer's disease: New therapeutic strategies]

Villegas S.

Med Clin (Barc). 2015 Jul 20;145(2):76-83. doi: 10.1016/j.medcli.2014.05.023. Epub 2014 Sep 20.

Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond

De Strooper B, Chávez Gutiérrez L.

Annu Rev Pharmacol Toxicol. 2015;55:419-37. doi: 10.1146/annurev-pharmtox-010814-124309. Epub 2014 Oct 1.

A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease

Newport MT, VanItallie TB, Kashiwaya Y, King MT, Veech RL.

Alzheimers Dement. 2015 Jan;11(1):99-103. doi: 10.1016/j.jalz.2014.01.006. Epub 2014 Oct 7.

Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment

Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L.

Biochim Biophys Acta. 2015 Jun;1852(6):1202-8. doi: 10.1016/j.bbadis.2014.10.006. Epub 2014 Oct 12.

Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights

Mehta DC, Short JL, Hilmer SN, Nicolazzo JA.

Pharm Res. 2015 Mar;32(3):819-39. doi: 10.1007/s11095-014-1522-0. Epub 2014 Oct 16.

Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease

Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM.

J Pharmacol Exp Ther. 2015 Jan;352(1):110-8. doi: 10.1124/jpet.114.219352. Epub 2014 Oct 15.

Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease

Han HJ, Kwon JC, Kim JE, Kim SG, Park JM, Park KW, Park KC, Park KH, Moon SY, Seo SW, Choi SH, Cho SJ.

Eur Neurol. 2015;73(1-2):23-8. doi: 10.1159/000366198. Epub 2014 Nov 1.

Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease

Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G; SWITCH study working group.

Neurol Sci. 2015 Mar;36(3):457-63. doi: 10.1007/s10072-014-2002-3. Epub 2014 Nov 14.

Role of insulin resistance in Alzheimer's disease

Cai Z, Xiao M, Chang L, Yan LJ.

Metab Brain Dis. 2015 Aug;30(4):839-51. doi: 10.1007/s11011-014-9631-3. Epub 2014 Nov 16.

Tropisetron and its targets in Alzheimer's disease

Hashimoto K.

Expert Opin Ther Targets. 2015 Jan;19(1):1-5. doi: 10.1517/14728222.2014.983901. Epub 2014 Nov 15.

Medical genetics-based drug repurposing for Alzheimer's disease

Zhang XZ, Quan Y, Tang GY.

Brain Res Bull. 2015 Jan;110:26-9. doi: 10.1016/j.brainresbull.2014.11.003. Epub 2014 Nov 22.

Improving the predictive value of interventional animal models data

Zeiss CJ.

Drug Discov Today. 2015 Apr;20(4):475-82. doi: 10.1016/j.drudis.2014.10.015. Epub 2014 Nov 4.

Pharmacotherapy of Alzheimer's disease: current and future trends

Geldenhuys WJ, Darvesh AS.

Expert Rev Neurother. 2015 Jan;15(1):3-5. doi: 10.1586/14737175.2015.990884. Epub 2014 Dec 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias